Scotiabank raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $53 from $51 and keeps an Outperform rating on the shares. The company has a strong quarter marked by continued achievement of important clinical development milestones, the analyst tells investors. With a favorable cash position, the firm believes the company is well-equipped to support the advancement of mitapivat in sickle cell disease, thalassemia, and its earlier clinical pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals Reports Robust Q3 2024 Results
- Agios Pharmaceuticals reports Q3 EPS $16.22, consensus $1.11
- Agios Pharmaceuticals (AGIO) Q3 Earnings Cheat Sheet
- Agios Pharmaceuticals completes enrollment of Phase 3 RISE UP study
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls